Rhumbline Advisers Increases Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Rhumbline Advisers increased its stake in shares of Catalent, Inc. (NYSE:CTLTGet Rating) by 14.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,845 shares of the company’s stock after purchasing an additional 38,001 shares during the quarter. Rhumbline Advisers’ holdings in Catalent were worth $31,849,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cetera Advisor Networks LLC increased its position in Catalent by 108.1% during the 2nd quarter. Cetera Advisor Networks LLC now owns 4,065 shares of the company’s stock worth $436,000 after purchasing an additional 2,112 shares in the last quarter. Bridgewater Associates LP increased its position in Catalent by 11.9% during the 2nd quarter. Bridgewater Associates LP now owns 20,509 shares of the company’s stock worth $2,200,000 after purchasing an additional 2,188 shares in the last quarter. Trexquant Investment LP purchased a new stake in Catalent during the 2nd quarter worth about $392,000. Deutsche Bank AG increased its position in Catalent by 6.5% during the 2nd quarter. Deutsche Bank AG now owns 455,707 shares of the company’s stock worth $48,893,000 after purchasing an additional 27,925 shares in the last quarter. Finally, Norris Perne & French LLP MI increased its position in Catalent by 1.3% during the 2nd quarter. Norris Perne & French LLP MI now owns 122,658 shares of the company’s stock worth $13,160,000 after purchasing an additional 1,628 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Analyst Ratings Changes

CTLT has been the subject of several recent analyst reports. Barclays lowered their price target on Catalent from $105.00 to $62.00 and set an “overweight” rating for the company in a report on Wednesday, November 2nd. TheStreet lowered Catalent from a “b-” rating to a “c+” rating in a research note on Friday, October 28th. Argus lowered Catalent from a “buy” rating to a “hold” rating in a research note on Monday, November 7th. KeyCorp reduced their price objective on Catalent from $125.00 to $85.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 2nd. Finally, UBS Group reduced their price objective on Catalent from $145.00 to $132.00 in a research note on Tuesday, August 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $92.80.

Catalent Stock Performance

Shares of CTLT opened at $42.18 on Thursday. The business’s 50 day moving average is $64.80 and its two-hundred day moving average is $89.93. Catalent, Inc. has a 52-week low of $40.69 and a 52-week high of $136.13. The firm has a market cap of $7.59 billion, a price-to-earnings ratio of 18.03, a PEG ratio of 1.83 and a beta of 1.30. The company has a quick ratio of 2.08, a current ratio of 2.86 and a debt-to-equity ratio of 0.87.

Catalent (NYSE:CTLTGet Rating) last announced its earnings results on Tuesday, November 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.24). Catalent had a net margin of 8.83% and a return on equity of 12.55%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Analysts forecast that Catalent, Inc. will post 3.12 EPS for the current fiscal year.

Insider Activity

In other news, SVP Michael J. Grippo sold 2,451 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $65.83, for a total value of $161,349.33. Following the completion of the sale, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Michael J. Grippo sold 2,451 shares of the company’s stock in a transaction on Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the completion of the transaction, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Thomas W. Hawkeswood sold 930 shares of the company’s stock in a transaction on Monday, October 10th. The stock was sold at an average price of $77.46, for a total value of $72,037.80. Following the transaction, the insider now owns 5,364 shares of the company’s stock, valued at $415,495.44. The disclosure for this sale can be found here. Company insiders own 0.58% of the company’s stock.

About Catalent

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Further Reading

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLTGet Rating).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.